Fig. 7: TRPV1 promotes cisplatin resistance through EGF-EGFR signaling pathway. | Nature Communications

Fig. 7: TRPV1 promotes cisplatin resistance through EGF-EGFR signaling pathway.

From: TRPV1 inhibition overcomes cisplatin resistance by blocking autophagy-mediated hyperactivation of EGFR signaling pathway

Fig. 7

a–c CaSki no insert and TRPV1 cells were treated with DMSO or AMG9810, as indicated. a The protein levels of TRPV1, LC3B, pEGFR, and EGFR were confirmed by western blots. b The frequency of apoptotic (active caspase 3+) cells were analyzed by flow cytometry. c The amount of EGF secreted into the media was measured by ELISA. d CaSki TRPV1 cells were treated with IgG or anti-EGF. Levels of pEGFR and EGFR were confirmed by western blots. e and f CaSki TRPV1 cells were transfected with siRNA targeting GFP or EGFR. e The protein levels of pEGFR and EGFR were confirmed by western blot analysis. f Flow cytometry analysis of the frequency of apoptotic (active caspase 3+) cells after incubation with or without cisplatin for 24 h. a, d, e β-actin was used as the internal loading control. Numbers below the blot images indicate the expression as measured by fold-change. All experiments were performed in triplicate. The p values by two-way ANOVA (b, f) or one-way ANOVA (c) are indicated. The data represent the mean ± SD. Source data are provided as a Source Data file. (NS, not significant).

Back to article page